Despite advances in neoadjuvant therapy and surgery, limited increase in the 5-year survival rate of patients with pancreatic adenocarcinoma (PDAC), implying the importance of post-operative management.
This study aims to achieve risk stratification of PDAC patients, providing regimen chosen guidance for clinicians and realizing precision treatment.
